静脉达比加群在兔模型体外循环中提供充分抗凝
该研究在10只新西兰白兔中建立体外循环(CPB)模型,分别给予静脉达比加群(6只)或肝素(4只)抗凝。达比加群组CPB期间血药浓度高于目标值,所有兔完成2小时CPB无可见血栓,脑、肾及滤器未见血栓或超微结构损伤,两组结局无显著差异。结论提示达比加群可能提供与肝素相似的可接受抗凝效果。
要点
- 兔CPB模型中静脉达比加群抗凝可防止血栓形成。
- 达比加群组CPB期间血药浓度高于预设目标90 µg/ml。
- 达比加群与肝素组在血栓及器官损伤结局上无显著差异。
核心结论
- 在兔CPB模型中,达比加群提供与肝素相似的可接受抗凝效果以预防血栓。
研究设计与样本
- 使用非线性混合效应模型在10只新西兰白兔中估计达比加群两室药代动力学参数。
- 动物接受胸骨切开术,6只给予静脉达比加群,4只给予肝素,经右心房和升主动脉插管建立CPB并维持120分钟。
主要发现
- CPB期间达比加群浓度高于目标值,5分钟为137 ± 40 μg/ml,60分钟为428 ± 150 μg/ml,120分钟为295 ± 35 μg/ml。
- 所有兔完成2小时CPB无可见血栓形成。
- CPB 120分钟时反应时间达比加群组为10,262 ± 4,198 s,肝素组为354 ± 141 s。
- 脑和肾未见血栓或超微结构损伤,动脉滤器切片显示极少或无纤维蛋白。
- 达比加群组与肝素组结局无显著差异。
临床怎么用
- 该首次概念验证研究提示达比加群可作为CPB抗凝的潜在替代方案,尤其适用于肝素诱导的血小板减少症情况。
局限性
- 研究为动物模型首次使用概念验证,样本量小(10只兔),结论需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heparin anticoagulation has been used successfully for cardiopulmonary bypass (CPB). However, an alternative anticoagulant approach is desirable due to the cases of heparin-induced thrombocytopenia. Dabigatran provides anticoagulation for an in vitro model of simulated CPB. The current analysis tests the hypothesis that dabigatran provides sufficient anticoagulation for CPB in intact rabbits. METHODS: Nonlinear mixed effects models were used to estimate dabigatran parameters for a two-compartment pharmacokinetic model in 10 New Zealand White rabbits. A dabigatran infusion designed to maintain a plasma concentration of 90 µg/ml was run throughout CPB based on the pharmacokinetics. Animals were subjected to sternotomy and anticoagulated with IV dabigatran (six animals) or heparin (four animals). Rabbits were cannulated centrally using the right atrium and ascending aorta and CPB was maintained for 120 min. Measurement of activated clotting time, thromboelastometric reaction time, and blood gases were performed during CPB. Then, the animals were euthanized, and the brain and one kidney were removed for histology. Sections of the arterial filters were inspected using electron microscopy. RESULTS: The observed dabigatran concentrations during CPB were greater than the target concentration, ranging from 137 ± 40 μg/ml at 5 min of CPB to 428 ± 150 μg/ml at 60 min, and 295 ± 35 μg/ml at 120 min. All rabbits completed 2 h of CPB without visible thrombosis. In the two groups, reaction time values were elevated, reaching 10,262 ± 4,198 s (dabigatran group) and 354 ± 141 s (heparin group) at 120 min of CPB. Brains and kidneys showed no evidence of thrombosis or ultrastructural damage. Sections of the arterial line filter showed minimal or no fibrin. There was no significant difference in outcomes between dabigatran- and heparin-treated animals. CONCLUSIONS: In this first-use, proof-of-concept study, the authors have shown that dabigatran provides acceptable anticoagulation similar to heparin to prevent thrombosis using a rabbit CPB model.
引用
- Nadtochiy SM, Stefanos T, Angona RE, et al. Intravenous Dabigatran Provides Adequate Anticoagulation for Cardiopulmonary Bypass Using a Rabbit Model. Anesthesiology. 2023. PMID: 36821759. doi:10.1097/ALN.0000000000004537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。